| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 4,530 | 5,720 | 5,750 | 4,780 | 4,780 |
| Sales Growth | -20.80% | -0.52% | +20.29% | unch | +132.04% |
| Net Income | -103,110 | -110,570 | -104,900 | -100,960 | -14,350 |
| Net Income Growth | +6.75% | -5.41% | -3.90% | -603.55% | -118.09% |
Absci Corp
(ABSI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.
Fiscal Year End Date: 12/31